UK tech transfer company signs licensing deal for Phase II endocrine product
This article was originally published in Scrip
Executive Summary
Fusion IP, which owns the rights to intellectual property generated at two UK universities – the University of Sheffield and Cardiff University, has signed a licensing deal with a pharmaceutical company utilising IP out of the University of Sheffield. Further details are being withheld for commercial reasons. The licence covers development of a known drug, in the area of certain endocrine diseases, in a market worth over $500 million per annum.
You may also be interested in...
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Pfizer/Astellas Amend Trial To Position Xtandi In Early Prostate Cancer
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.